2026 Q1 Earnings Results IR Meeting
-
Purpose: Announce 2026 Q1 preliminary earnings and R&D session
-
Date/Time: 2026-05-07 10:30, conference call format
-
Participants: Domestic and foreign investors and analysts
-
Presentation materials and live audio webcasting will be posted on the website on the same day.
KOSPI Filing Information
-
Filing: Corporate Briefing (IR) Holding (Notice Disclosure)
-
Company: SK Biopharmaceuticals (326030)
-
Submission: SK Biopharmaceuticals Co., Ltd.
-
Receipt: 05-04-2026
-
Under KRX KOSPI Market Division